| Literature DB >> 34487041 |
Dennis van de Veen1,2,3, Christian Bakker1,2,4, Kirsten Peetoom5, Yolande Pijnenburg6, Janne M Papma7, Marjolein de Vugt7, Raymond Koopmans1,2,8.
Abstract
BACKGROUND: There has been growing interest in young people living with dementia. Future research requires consensus on the terminology and operational definition of this group.Entities:
Keywords: Definition; operationalization; young-onset dementia
Mesh:
Year: 2021 PMID: 34487041 PMCID: PMC8609678 DOI: 10.3233/JAD-210458
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472
Category 1 terminology and definitions of dementia at a young age
| Authors (y) | Study | Term(s) | Age-related aspects | Etiologies† | Quality | |||||
| Design | Population (n) | Setting | Upper age limit | Lower age limit | Subdivision | Diseases ‡ | Categories | +, ±, or – | ||
| Ahmed et al. (2016) [ | Symposium paper | n/a | n/a | Young-onset dementia | 65 | n/a | n/a | 1, 1a, 2a, 2b, 2c-i, 2c-ii, 2c-iii, 3, 4, 5, 6, 7, 8, 29a, 30, 31, 33, 35, 39, 42a, 43, 43a, 43c, 45, 46, 58a, 60, 62, 64, 67, 69, 71, 73, 77, 78a, 80, 82, 86, 87, 111, 133, 135, 136, 145, 147, 148a | I, II, III, IV, IVa, Va, Vb, Vc, IXc, XI | Good |
| Charlton (1975) [ | Opinion | n/a | n/a | Presenile dementia | n/a | n/a | n/a | 1, 2, 4, 5, 8, 10, 14, 29, 31, 33, 46, 58a, 60, 73f, 73g, 76, 77b, 77h, 78, 78a, 78b, 78d, 80, 87, 133, 135, 136, 145, 149, 150, 152, 153, 157, 160 | II, IV, Va, Vb, IXb, IXc, XIV | Good |
| Coblentz et al. (1973) [ | Prospective study | 30 | Hospital | Presenile dementia | 65 | n/a | n/a | 1, 2, 32, 40, 58a, 135 | IV, X | Good |
| Cowie (1981) [ | Opinion | n/a | n/a | Presenile dementia | n/a | n/a | n/a | 1, 2, 8, 58a, 87 | n/a | Good |
| Davies et al. (2011) [ | Review | n/a | n/a | Presenile dementia, early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2a, 2c-i, 2c-ii, 30, 31, 33, 34, 39, 42a-ii, 43b, 57, 58, 58a, 61a, 73, 73c, 77e, 86, 133, 135, 136, 138, 147, 150, 151, 152, 159 | I, II, III, IV, Vb, IX, X, XI, XIIb | Good |
| Dixon (2007) [ | Opinion | n/a | n/a | Early-onset dementia, young-onset dementia | 60, 65 | n/a | n/a | 1 | n/a | Adequate |
| Doran (1997) [ | Opinion | n/a | n/a | Presenile dementia | 65 at diagnosis | 16 | n/a | 1, 2, 2d, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 26, 28, 29, 29a, 29b, 30, 31, 35, 35c, 37, 39, 41, 42a, 43, 43a, 43b, 43e, 43f, 43g, 45, 51, 54, 57, 58a, 58c, 59, 60, 62, 64, 67, 69, 72, 73, 73c, 73e, 75, 76, 77g, 78, 87, 88, 91, 93, 103, 110, 112, 113, 114, 115, 116, 117, 118, 120, 124, 125, 126, 130, 131, 132, 133, 135, 140, 141, 142, 146 | I, II, III, IV, Va, Vb, | Good |
| Draper and Withall (2016) [ | Review | n/a | n/a | Young onset dementia | 65 at symptom onset | n/a | 30–44, 45–64 | 1, 2, 3, 4, 5, 6, 8, 12, 14, 14a, 29, 30, 39, 42a, 43b, 43c, 57, 58a, 60, 67, 73, 73c, 87, 109, 110, 111, 112, 135, 162 ‡ | I, IV, Vb, IXc, XV | Good |
| Fadil et al. (2009) [ | Review | n/a | n/a | Early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2a, 2b, 2c-i, 2c-ii, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 23, 29, 29a, 29b, 30, 31, 33, 33a, 39, 41, 42, 42a, 43, 43a, 43b, 43c, 45, 46, 49, 50, 57, 58, 58a, 58b, 58c, 58d, 59, 60, 61, 62, 67, 69, 70, 71, 72, 73c, 73e, 73f, 76, 77, 77b, 77c, 77f, 78a, 78c, 82, 84, 86, 87, 88, 89, 90, 133, 134, 135, 136, 139, 140, 141, 142, 143, 145, 148, 151, 152, 153, 155, 161, 167 | I, II, IV, Va-Vb, VI, VIII, IXc, X, XI, XV | Good |
| Forbes (2005) [ | Book review | n/a | n/a | Presenile dementia, early-onset dementia | 65 | n/a | n/a | 1, 2, 2c-i, 2c-ii, 3, 8, 58, 58a | III | Good |
| Giannakopoulos et al. (1996) [ | Review | n/a | n/a | Early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2e | I, II, III, IXb, IXc | Good |
| Gibson (1960) [ | Opinion | n/a | n/a | Presenile dementia | 65 | Covers from 40, occurs in much younger | n/a | 1, 2, 8, 58a | n/a | Adequate |
| Goldman (2015) [ | Review | n/a | n/a | Early-onset dementia, young-onset dementia | 60 | n/a | n/a | 1, 2, 2a, 3, 4, 8, 9, 12, 14, 19, 29, 30, 58, 58a, 58b, 58c, 59, 87, 104, 108, 110, 111, 112, 120, 121, 125, 126, 130 | I, Vb, VI, XVI | Good |
| Goodall (1938) [ | Discussion | n/a | n/a | Presenile dementia | 60 at symptom onset | Usually 40 | n/a | 1, 2, 8, 39, 58a, 60, 60a, 60b, 66, 73, 73d, 73e, 77a, 77b, 78a, 79, 80, 133, 136, 137, 147 | II, Va, IXb, XIV, XVII, XVIII, XIX | Adequate |
| Greicius et al. (2002) [ | Review | n/a | n/a | Presenile dementia | 60 | n/a | n/a | 1, 2, 2a, 2c-i, 2c-ii, 3, 5, 6, 58, 58a, 58c, 58d, 59 | n/a | Good |
| Harvey (1998) [ | Theoretical thesis | n/a | n/a | Young onset dementia, presenile dementia | 60, 65, 70, at symptom onset, diagnosis, at presentation to medical services | 30, 35 | 30–44, 45–64 | 1, 2, 3, 4, 5, 6, 8, 29, 29a, 30, 31, 33, 39, 57, 58, 58a, 58b, 73, 73c, 73e, 73f, 73g, 82, 135, 161, 169, 172 | n/a | Good |
| Hayo (2015) [ | Review | n/a | n/a | Young-onset dementia, younger people with dementia, early-onset dementia, working age dementia | 65 year at diagnosis | n/a | 35–45, 45–65 | 1, 1a, 2, 3, 4, 5, 6, 8, 29, 39, 57, 58a, 73, 110, 135, 150, 131, 161 | I, IVa, Vb, Vc, XX | Good |
| Koopmans and Rosness (2014) [ | Editorial | n/a | n/a | Presenile dementia, early-onset dementia, younger-onset dementia, young-onset dementia | 65, 45 at symptom onset or at diagnosis | 17 | n/a | 1 | n/a | Good |
| Kuruppu and Matthews (2013) [ | Review | n/a | n/a | Young-onset dementia | 65 | Typically 45 | n/a | 1, 2, 3, 7, 8, 17, 29, 30, 35, 39, 42, 42a, 43a, 45, 57, 58a, 60, 67, 71, 73, 73e, 73f, 77, 78, 81, 86, 87, 104, 105, 106, 108, 109a, 109b, 110, 111, 112, 120, 121, 122, 123, 124, 125, 126, 145, 147, 150, 151, 152, 157 ‡ | III, IV, Va, Vc, VI, VII, VIII, XI | Good |
| Laino (2005) [ | Interview about prospective study | 278 | Home | Early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 57, 60, 73, 73f, 134, 135, 151 | n/a | Adequate |
| Levine (2013) [ | Opinion | n/a | n/a | Young-onset dementia | 65 | n/a | n/a | n/a | I, II, III, IV, Vb, XIII, XV | Good |
| Liebson et al. (2005) [ | Opinion | n/a | n/a | Early-onset dementia | n/a | n/a | n/a | 1, 2, 3, 4, 8, 9, 29, 39, 46, 57, 58a, 60, 73, 73f, 77, 134, 135, 147, 147a, 153, 154, 157, 159, 165, 166, 168 | XVIII, XXI | Good |
| Masellis et al. (2013) [ | Review | n/a | n/a | Early-onset dementia, young-onset dementia | 45, 65 year at symptom onset | Early adult-hood | 30–45, 45–65 | 1, 2, 2a, 2c, 2c-i, 2c-ii, 2c-iii, 3, 4, 5, 6, 10, 14, 14a, 19, 29a, 30, 34, 35, 42, 42a, 43, 43b, 44, 49, 57, 60, 62, 73c, 73f, 86, 87, 104, 108, 109, 110, 111, 112, 114, 120, 121, 126, 129, 130, 133, 140, 147b, 153 ‡ | I, II, III, IV, Vb, Vc, IXc, X, XI | Good |
| Miyoshi (2009) [ | Review | n/a | n/a | Presenile dementia, early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2c-i, 2c-ii, 5, 6, 17, 29, 30, 35a, 35g, 57, 70, 134 | I, II, Va, Vb, IX | Good |
| Moffie (1953) [ | Review | n/a | n/a | Presenile dementia | 65 | 45 | n/a | 1, 2, 8, 48, 168a | II | Adequate |
| NHMRC National Institute for Dementia Research (2020) [ | Theoretical abstract book | n/a | n/a | Young-onset dementia, younger-onset dementia, early-onset dementia, adult-onset dementia, childhood dementia | 65, at symptom onset, before deceased (“died aged less than”) | n/a | n/a | 1, 2, 2a, 3, 4, 110, 161 | I | Good |
| Panegyres et al. (2000) [ | Letter to the editor | n/a | n/a | Early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2a, 2c, 2c-i, 3, 4, 5, 29, 57, 58a, 59, 73, 159 | XIIb | Good |
| Pinhorn (1993) [ | Letters to the editor | n/a | n/a | Presenile dementia | 65 | 40 | n/a | 1, 29, 31, 73, 134 | n/a | Adequate |
| Poser (1975) [ | Opinion | n/a | n/a | Presenile dementia | n/a | n/a | n/a | 1, 2, 4, 8, 29, 47, 58a, 60, 73, 73c, 73f, 77b, 77i, 77j, 84, 135, 150, 153, 154, 169 | n/a | Good |
| Ridha and Josephs (2006) [ | Review | n/a | n/a | Young-onset dementia | 65 at symptom onset | n/a | n/a | 1, 1a, 2, 2b, 2c, 2c-i, 2d, 2f, 3, 4, 5, 6, 8, 10, 11, 12, 13b, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 28, 29, 30, 35a, 35b, 35c, 35d, 35e, 35f, 37, 38, 39, 42, 42a, 43, 43a, 43b, 43d, 43h, 41, 52, 53, 54, 56, 58, 60, 61a, 61b, 62, 63, 64, 65, 67, 68, 69, 71, 72, 73, 73e, 73f, 74, 75, 76, 77, 77c, 77h, 77k, 77l, 77m, 78a, 78e, 80, 82, 83, 85, 86, 87, 88, 91, 92, 93, 94, 96, 102, 109, 110, 112, 114, 117, 119, 121, 123, 125, 126, 127, 128, 129, 130, 131, 123, 136, 141, 147a, 150, 152a, 152b, 156, 157, 158, 159, 162, 163, 164, 170, 171 | IV, Vb, VI, VII, XIV | Good |
| Risien Russel (1933) [ | Discussion | n/a | n/a | Presenile dementia | 60, 65 at symptom onset | Usually 30, 40 | n/a | 1, 2, 8, 39, 66, 73, 73a, 73d, 80 | I, II, IV-Va, IXb, IXc, XVII | Adequate |
| Rossor et al. (2010) [ | Review | n/a | n/a | Young-onset dementia | 65, 45 at symptom onset | 18, 30 | <35, 35–45, 45–65 | 1, 1a, 2, 2a, 2b, 2c-i, 2c-ii, 2d, 2f, 3, 4, 5, 7, 8, 10, 12, 13a, 13b, 13c, 14, 14a, 14b, 14c, 14d, 15, 19, 20, 22, 23, 24, 25, 27, 30, 35, 35a, 35b, 39, 42, 42a, 42b, 43c, 43d, 49, 51, 57, 58, 58b, 59, 60, 61a, 64, 69, 73, 73f, 86, 87, 88, 92, 94, 99, 100, 101, 102, 107, 109, 110, 111, 112, 114, 115, 117, 120, 121, 122, 123, 125, 126, 130, 131, 145, 147 ‡ | III, IV, Va, Vb, VI, XIII | Good |
| Sampson et al. (2004) [ | Review | n/a | n/a | Young onset dementia | 60, 65 | 20, 30, 45 | 45–65 | 1, 2, 2a, 2b, 2c-i, 2c-ii, 3, 4, 5, 6, 7, 8, 10, 14, 15, 16, 19, 20, 23, 29, 29a, 30, 31, 33, 35, 35a, 35b, 35c, 35d, 35e, 39, 41, 42a, 43, 43a, 43b, 43c, 45, 46, 49, 57, 58a, 58b, 58c, 59, 60, 61a, 61b, 62, 64, 65, 67, 69, 70, 71, 73, 73c, 77, 77c, 77d, 78a, 80, 82, 86, 87, 94, 102, 109b, 110, 111, 112, 114, 117, 120, 121, 124, 125, 126, 130, 131, 133, 135, 136, 141, 145, 147, 161 ‡ | I, II, III, IV, Va, Vb, Vc, VI, VII, IXc, XI, XII | Good |
| Sitek et al. (2015) [ | Review | n/a | n/a | Early-onset dementia, young-onset dementia | 65 | n/a | n/a | 1, 1a, 2, 2a, 2c, 2c-i, 2c-ii, 2c-iii, 3, 5, 6, 8, 29, 135 | I, IV, Va, VI, X, XV | Good |
| Tonkonogy and Moak (1988) [ | Opinion | n/a | n/a | Presenile dementia | 50, 55 at symptom onset | n/a | n/a | 1, 29, 60, 60a, 73b | n/a | Good |
| Werner et al. (2009) [ | Review | n/a | n/a | Presenile dementia, early-onset dementia | 65 | n/a | 45–65 | 1, 2, 3, 4, 5, 8, 9, 29, 43, 57, 73, 77, 133, 134 | n/a | Good |
† See Table 4. ‡ Including dementia plus syndromes.
Etiologies in category 1 literature, subdivided in categories
| I. Primary neurodegenerative disorders |
| 1 Alzheimer’s disease (including: 1a posterior cortical atrophy (PCA)), 2 frontotemporal lobe degeneration (FTLD)/Pick’s disease (including: 2a behavioral variant frontotemporal dementia (bvFTD)/frontal variant, 2b motor neuron disease (mnFTD), 2c primary progressive aphasia (PPA), including: 2c-i semantic dementia (SD)/temporal variant, 2c-ii progressive nonfluent aphasia (PNFA), 2c-iii logopenic variant, 2d FTD and parkinsonism linked to chromosome 17 (FTDP-17), 2e dementia lacking distinctive histopathology (DLDH), 2f inclusion body myopathy associated with Paget disease and FTD (IBMPFTD)), 3 dementia with Lewy bodies (LBD), 4 Parkinson’s disease dementia, 5 progressive supranuclear palsy (PSP)/Steele-Richardson-Olszewski syndrome, 6 corticobasal degeneration (CBD), 7 multiple system atrophy (MSA), 8 Huntington’s disease, 9 amyotrophic lateral sclerosis (ALS), 10 pantothenate kinase-associated degeneration or neurodegeneration with iron accumulation (PKAN/NBIA/Hallervorden-Spatz syndrome), 11 aceruloplasminemia, 12 neuroacanthocystosis (McLeod’s syndrome), 13a Huntington chorea-like type 1 (HDL1), 13b HDL2, 13c HDL3, 14 spinocerebellar ataxia (SCA) (including: 14a fragile X tremor ataxia syndrome (FXTAS), 14b SCA type 2, 14c SCA type 12, 14d SCA type 17), 15 familial encephalopathy with neuroserpin inclusion bodies (FENIB), 16 neuronal intermediate filament inclusion disease (NIFID)/neurofilament inclusion body disease, 17 diffuse (cortical) neurofibrillary tangle (disease) with calcification (DCNTDC/DNTC)/Kosaka-Shibayama disease/Fahr’s syndrome, 18 hereditary hemochromatosis, 19 dentatorubral-pallidoluysian atrophy (DRPLA), 20 Lafora body disease, 21 Mohr-Tranebjaerg syndrome, 22 myotonic dystrophy type 3, 23 neuroferritinopathy, 24 giant axonal neuropathy (GAN), 25 progressive myoclonic epilepsy syndrome (PME), 26 intranuclear inclusion body disease (INIBD)/neuronal intranuclear inclusion disease (NIID), 27 Perry syndrome, 28 hereditary sensory neuropathy type IE. |
| II. Cerebrovascular dementias |
| 29 Vascular dementia (including: 29a small vessel disease (SVD), 29b large vessel disease), 30 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)/Binswanger disease, 31 multi-infarct dementia, 32 microinfarcts, 33 strategic infarct dementia (including: 33a thalamic dementia), 34 vascular cognitive impairment, 35 cerebral amyloid angiopathy (CAA) (including: 35a familial British dementia/English-type amyloid angiopathy, 35b familial Danish dementia, 35c Dutch variant of hereditary cerebral haemorrhage with amyloidosis, 35d hereditary cerebral haemorrhage with amyloidosis of Icelandic type, 35e meningovascular amyloidosis, 35f familial amyloidosis of Finnish type, 35g hereditary cerebral haemorrhage with amyloidosis), 36 Sneddon’s syndrome, 37 antiphospholipid syndrome, 38 Susac syndrome. |
| III. Inflammatory diseases |
| 39 Multiple sclerosis (MS), 40 Meningeal irritation, 41 chronic meningitis, 42 paraneoplastic syndromes (including: 42a limbic encephalitis, including 42a-i paraneoplastic limbic encephalitis (PNLE), 42a-ii non-paraneoplastic limbic encephalitis (NPLE), 42b anti-NMDA receptor-mediated limbic encephalitis), 43 primary central nervous system vasculitis (PACNS)/primary central nervous system angiitis (including: 43a neuro-Behçet, 43b systemic lupus erythematosus (SLE) 43c systemic vasculitides, 43d autoimmune connective tissue disorders, 43e polyarteritis, 43f nodosa, 43g Wegener’s syndrome, 43h rheumatoid arthritis), 44 secondary central nervous system vasculitis, 45 neurosarcoidosis, 46 hepatic encephalopathy, 47 chronic obstructive pulmonary disease (COPD), 48 Bürger’s disease, 49 Hashimoto’s encephalopathy, 50 nonvasculitic autoimmune inflammatory meningoencephalitis, 51 celiac disease, 52 pancreatic encephalopathy, 53 antibasal ganglia antibodies (AGBA), 54 Sjögren syndrome, 55 cryoglobulinemia, 56 atrophic gastritis. |
| IV. Infectious diseases (including IVa Prion diseases) |
| 57 Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) dementia complex, 58 prion diseases/transmissible spongiform encephalopathy (TSE) (including: 58a Creutzfeldt-Jakob disease (CJD), 58b new variant Creutzfeldt-Jacob disease (vCJD)/bovine spongiform encephalopathy (BSE), 58c Gerstmann-Sträussler-Scheinker syndrome, 58d Kuru), 59 fatal familial insomnia, 60 neurosyphilis (including: 60a general paresis of the insane, 60b luetic cerebrovascular disease), 61 cytomegalovirus encephalitis (including: 61a herpes simplex encephalitis, 61b herpes zoster), 62 Lyme disease, 63 immune thrombocytopenic purpura (ITP), 64 tuberculosis, 65 fungal infection, 66 epidemic encephalitis/encephalitis lethargica, 67 Whipple’s disease, 68 infective endocarditis, 69 subacute sclerosing panencephalitis (SSPE), 70 neurocysticercosis, 71 progressive multifocal leukoencephalopathy, 72 toxoplasmosis. |
| Va. Toxic diseases/Vb. metabolic diseases/Vc. nutritional deficiencies |
| 73 Alcohol-related dementias/alcohol abuse (including: 73a Wernicke syndrome, 73b Korsakoff syndrome, 73c Wernicke-Korsakoff syndrome, 73d presbyophrenia, 73e niacin deficiency/pellagra, 73f vitamin B12/thiamine deficiency, 73g Marchiafava-Bignami disease), 74 vitamin D deficiency, 75 vitamin E deficiency, 76 vitamin B9/folate deficiency, 77 drug-related dementias (including: 77a hashish, 77b barbiturates, 77c lithium, 77d interferon, 77e anti-cholinergic medication, 77f cocaine abuse, 77g methotrexate, 77h psychotropic drugs, 77i bromide, 77j phenothiazines, 77k valproate, 77l antiparkinson medication, 77m ceftazidime toxicity), 78 heavy metal poisoning (including: 78a lead, 78b mercury, 78c arsenic, 78d manganese, 78e aluminium), 79 subacute combined degeneration of the cord/Lichtheim’s disease/Putnam-Dana syndrome, 80 uraemia, 81 metabolic encephalopathy, 82 carbon monoxide poisoning, 83 hyperammonaemic encephalopathy/ citrullinemia, 84 renal failure and dialysis dementia, 85 citrullinemia, 86 obstructive sleep apnoea-hypnoea syndrome, 87 Wilson’s disease, 88 porphyria, 89 electrolyte abnormalities, 90 Bismuth toxicity, 91 homocystinuria, 92 superficial siderosis, 93 mucopolysaccharidosis III, 94 ornithine transcobalamine deficiency, 95 ceftazidime toxicity, 96 abetalipoproteinemia, 97 galactosialidosis, 98 mannosidosis, 99 phenylketonuria (PKU), 100 hereditary spastic paraparesis (HSP/SPG4), 101 Lesch-Nyhan syndrome, 102 anti-voltage-gated potassium channel antibody syndrome (VGKC-Ab), 103 Leigh syndrome/subacute necrotizing encephalomeylopathy. |
| VI. Mitochondrial disorders |
| 104 Mitochondrial myopathy encephalopathy lactic acidosis and stroke (MELAS), 105 myoclonic epilepsy with ragged-red fibers (MERRF), 106 Kearns-Sayre syndrome, 107 DNA polymerase subunit gamma (POLG)-related disease. |
| VII. Lysosomal storage disorders |
| 108 Tay-Sachs disease, 109 Gaucher’s disease (including: 109a type 2, 109b type 3), 110 Niemann-Pick disease type C, 111 Fabry’s disease, 112 neuronal ceroid lipofuscinosis (Kuf’s disease or Batten disease), 113 GM 1 gangliosidosis, 114 GM2 gangliosidosis, 115 alpha mannosidosis, 116 adult Chediak-Higashi syndrome, 117 sialidosis (mucolipidosis I), 118 aspartylglucosaminuria. |
| VIII. Leukodystrophies |
| 119 X-linked adrenoleukodystrophy, 120 adrenoleukodystrophy, 121 metachromatic leukodystrophy, 122 Alexander’s disease, 123 leukoencephalopathy with vanishing white matter, 124 Pelizaeus-Merzbacher disease, 125 adult polyglucosan body disease, 126 cerebrotendineous xanthomatosis, 127 pigmentary orthochromatic leukodystrophy (POLD), 128 hereditary endotheliopathy with retinopathy nephropathy stroke (HERNS), 129 hereditary diffuse leukoencephalopathy with spheroids (HDLS), 130 Krabbe disease (globoid cell leukodystrophy), 131 polycystic lipomembranous leukodystrophy with sclerosing leukoencephalopathy (PLOSL/Nasu-Hakola disease), 132 Canavan disease. |
| IXa. Structural disorders/IXb. head injury/IXc. (para)neoplastic/metastatic |
| 133 Cerebral tumors and abscess, 134 traumatic brain injury/head trauma, 135 normal pressure hydrocephalus, 136 subdural hematoma, 137 sequelae of cerebral laceration, 138 dural arteriovenous fistula, 139 brain metastatic disease, 140 primary central nervous system lymphoma, 141 intravascular lymphoma, 142 lymphomatoid granulomatosis, 143 gliomatosis cerebri, 144 malignant melanoma, 145 chronic traumatic encephalopathy/dementia pugilistica, 146 hypereosinophilic syndrome. |
| X. Reversible disorders/treatable causes |
| 147 Epileptic dementias (including: 147a temporal lobe epilepsy, 147b mesiotemporal lobe epilepsy), 148 iatrogenic disorders/adverse effects of prescribed medication (including: 148a post-irradiation lower motor neuron syndrome), 149 transient global amnesia (TGA). |
| XI. Endocrine disorders |
| 150 Diabetes mellitus, 151 thyroid disease, 152 parathyroid disease (including: 152a hypoparathyroidism, 152b hyperparathyroidism), 153 hypothyroidism, 154 hyperthyroidism, 155 adrenal disease, 156 nonketonic hyperosmolar hyperglycaemia, 157 Cushing disease, 158 Addison disease, 159 pseudohypoparathyroidism, 160 hypopituitarism. |
| XII. Other (XIIa developmental disorders, XIIb psychiatric disorders) |
| 161 Down’s syndrome (trisomy 21), 162 depression, 163 anxiety, 164 conversion disorders, 165 mania, 166 schizophrenia. |
| XIII. Genetic disorders, XIV. hereditary disorders/heredo-degeneration, XV. (auto)immune, XVI. movement disorders, XVII. syphilitic dementias, XVIII. secondary dementias, XIX. dementia complicating chronic disorders, XX. multi-system failure, XXI. cerebral atrophy. |
| 167 Immune-mediated diseases, 168 cerebellar atrophy (including: 168a olivopontocerebellar atrophy), 169 chronic hypoxia, 170 paroxysmal cardiac arrhythmia, 171 ureterosigmoidostomy, 172 acquired hepatocerebral degeneration. |
Fig. 1Data evaluation process.
Overview of different terms and age-related aspects
| Aspect | Frequency category 1 | Frequency category 2 |
| Nomenclature | ||
| Presenile dementia | 18 | 20 |
| Early-onset dementia | 16 | 22 |
| Young-onset dementia | 15 | 19 |
| Younger-onset dementia | 3 | 6 |
| Adult-onset dementia | 1 | 0 |
| Working-age dementia | 1 | 0 |
| Childhood dementia | 1 | 0 |
| Age-related aspects Upper age limit | ||
| 45 years | 3 | 3 |
| 50 years | 1 | 0 |
| 55 years | 1 | 0 |
| 60 years | 7 | 3 |
| 65 years | 28 | 41 |
| 70 years | 1 | 1 |
| Age criterium | ||
| Age at symptom onset | 12 | 18 |
| Age at diagnosis | 4 | 6 |
| Age at presentation to medical services | 1 | 0 |
| Age before deceased | 1 | 0 |
| Lower age limit | ||
| 16 years (incl early adulthood) | 2 | 0 |
| 17 years | 1 | 3 |
| 18 years | 1 | 0 |
| 20 years | 1 | 3 |
| 21 years | 0 | 2 |
| 30 years | 4 | 5 |
| 35 years | 1 | 1 |
| 40 years | 4 | 1 |
| 45 years | 3 | 2 |
| Subdivision | 7 | 7 |
Random sample category 2 terminology and definitions of dementia at a young age
| Authors (y) | Study | Term(s) | Age-related aspects | Etiologies† | |||||
| Design | Population (n) | Setting | Upper age limit | Lower age limit | Subdivision | Diseases | Categories | ||
| “Spotting early onset dementia” (2016) [ | Announcement | n/a | n/a | Early onset dementia | 65 | n/a | n/a | n/a | n/a |
| Allen and Baldwin (1995) [ | Case-control study | 28 | Home | Presenile dementia | 65 | n/a | n/a | 1, 2, 31, 73 Exclusion: 2b, 5, 8, 39, 81, 99, 145, 147, 169 | n/a Exclusion: IXb, XIIb, IXb |
| Andrew et al. (2019) [ | Review | n/a | n/a | Younger onset dementia | 65 | n/a | n/a | n/a | n/a |
| Appelhof et al. (2019) [ | Randomized controlled trial | 274 | Nursing home | Young-onset dementia | 65 | n/a | n/a | 1, 2, 3, 4, 29, 73 Exclusion: 8, 57, 73b, 134, 161 | n/a |
| Armari et al. (2013) [ | Case-control study | 83 | Home | Early onset dementia | 65 | 45 | n/a | 1, 2 | n/a |
| Arvanitakis et al. (2019) [ | Review | n/a | n/a | Young onset dementia | 65 | n/a | n/a | 1, 2, 3, 29 | n/a |
| Balasa et al. (2014) [ | Cohort study | 157 | Home | Early-onset dementia | 65 at diagnosis | n/a | n/a | 1, 1a, 2, 2c | XIIb |
| Belhouane et al. (2012) [ | Cross sectional study | 1685 | Hospital | Early onset dementia | 65 at symptom onset | n/a | n/a | 1, 29 | I, III, Vb |
| Carter et al. (2018) [ | Review | n/a | n/a | Young-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2a | n/a |
| Cations et al. (2019) [ | Review | n/a | n/a | Young onset dementia | 60, 65 at symptom onset | n/a | <45; 45–65 | 1, 29, 73,134, 145 | n/a |
| Dale (2000) [ | Comment | n/a | n/a | Presenile dementia | n/a | n/a | n/a | 1, 2 | n/a |
| Devineni and Onyike (2015) [ | Review | n/a | n/a | Young-onset dementia, early-onset dementia, presenile dementia | 65, 45 | 17, 20, 35, 45 | n/a | 1, 1a, 2, 2a, 2c, 2c-i, 2c-ii, 2c-iii, 3, 4, 5, 6, 8, 9, 14, 29, 58a, 73, 134 | I, II, IVa, IV, Vb, Vc, XIII, XV |
| Diehl-Schmid et al. (2018) [ | Protocol paper | n/a | n/a | Young-onset dementia | 65 at symptom onset | n/a | n/a | n/a | n/a |
| Draper et al. (2016) [ | Cohort study | 88 | Home | Young-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 3, 5, 8, 29, 73 | n/a |
| Dumitru et al. (2014) [ | Cross sectional study | 350 | Hospital | Early-onset dementia | 65 | n/a | n/a | 1, 2, 29, 73, 134 | n/a |
| Filipovic and Kostic (1995) [ | Randomized controlled trial | 137 | Home | Presenile dementia | 65 | n/a | n/a | 1, 4, 8, 31 | n/a |
| Fujihara et al. (2004) [ | Cross sectional study | 141 | Hospital | Presenile dementia, early-onset dementia | 65 at symptom onset | 21 | n/a | 1, 2, 4, 5, 29, 39, 43, 49, 70, 73, 121, 134, 135, 162, 169 | Vb |
| Garre-Olmo et al. (2010) [ | Cross sectional study | 2083 | Hospital | Early-onset dementia | 65 at symptom onset | 30 | n/a | 1, 2, 2a, 2c-i, 3, 4, 5, 6, 8, 29, 58a, 73, 134 | n/a |
| Giebel et al. (2020) [ | Cohort study | 11 | Home | Young-onset dementia | 65 at diagnosis | n/a | n/a | 1, 2, 29 | n/a |
| Gordon (1968) [ | Cohort study | 13 | Home | Presenile dementia | n/a | n/a | n/a | 1, 2, 58a | n/a |
| Gottfries et al. (1969) [ | Cohort study | 77 | Home | Presenile dementia | n/a | n/a | n/a | n/a | n/a |
| Guermani et al. (2013) [ | Cross sectional study | 50 | Hospital | Early onset dementia | n/a | n/a | n/a | n/a | n/a |
| Gustafson and Nilsson (1982) [ | Cohort study | 57 | Home | Presenile dementia | 65 | 40 | n/a | 1, 2, 31, 49, 58a, 135 | I, II |
| Harvey et al. (2003) [ | Cross sectional study | 227 | Hospital | Young-onset dementia | 65 | 30 | 30–44, 45–64 | 1, 2, 3, 4, 6, 8, 29, 39, 73, 161 | IVa |
| Henley et al. (2014) [ | Project description | n/a | n/a | Young-onset dementia, early-onset dementia | 65 at diagnosis | n/a | n/a | 1, 1a, 2, 2a, 2c, 3, 4, 5, 8 | n/a |
| Hutchinson et al. (2016) [ | Cohort study | 12 | Home and nursing home | Younger-onset dementia | 65 | 30 | n/a | 1 | n/a |
| Hvidsten et al. (2019) [ | Cohort study | 88 | Nursing home | Young-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2a, 2c | n/a |
| Ikejima et al. (2009) [ | Cross sectional study | 617 | Hospital | Early-onset dementia, presenile dementia | 65 at symptom onset | 20 | n/a | 1, 3, 4, 29, 30, 31, 33, 73, 133, 134, 169 Exclusion: 162, 166 | IV Exclusion: XIIa |
| Jefferies and Agrawal (2009) [ | Review | n/a | n/a | Early-onset dementia, young-onset dementia | 65 | 30 | n/a | 1, 2, 2a, 2c, 2c-i, 3, 8, 29, 29a, 30, 31, 33, 57, 58a, 73 Exclusion: 39, 43, 43b, 45, 61a, 73b, 73f, 77, 134, 135, 162, 169, delirium, amnestic syndromes, MCI, pseudodementia, stroke, encephalitis, dissociative disorders, benzodiazepines | IVa Exclusion: XI |
| Johannessen et al. (2014) [ | Cross sectional study | 20 | Home | Young onset dementia | 65 at diagnosis | n/a | n/a | 1 | n/a |
| Kaszniak et al. (1978) [ | Cohort study | 47 | Nursing home | Presenile dementia | n/a | n/a | n/a | n/a | n/a |
| Kelley et al. (2008) [ | Cross sectional study | 235 | Hospital | Young-onset dementia, early onset dementia | 65, 45 at symptom onset | 17, 21, 30 | 30–44, 45–65 | 1, 1a, 2, 2d, 3, 4, 5, 6, 8, 10, 12, 14, 17, 25, 29, 30, 31, 39, 43, 43b, 50, 57, 71, 73, 87, 108, 110, 112, 120, 121, 123, 129, 133, 135, 142 | I, II, III, IV, IVa, Va, Vb, VI, VII, X, XIV |
| Kilty et al. (2019) [ | Cross sectional study | 6 | Home and nursing home | Young onset dementia | 65 | n/a | n/a | n/a | n/a |
| Koopmans et al. (2015) [ | Editorial | n/a | n/a | Young-onset dementia | 65 at symptom onset | n/a | 30–44, 45–65 | 1 | n/a |
| Kurz et al. (2016) [ | Protocol paper | n/a | n/a | Young-onset dementia | 65 at symptom onset | n/a | n/a | 1 | n/a |
| Liddell (1958) [ | Cohort study | 11 | Hospital | Presenile dementia | n/a | n/a | n/a | n/a | n/a |
| Maiovis et al. (2015) [ | Cross sectional study | 491 | Hospital | Early onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 2a, 2c-i, 2c-ii, 3, 5, 6 | I, II, III, IV, Va, Vb, IXc, XIII |
| McMurtray et al. (2006) [ | Cross sectional study | 1683 | Hospital | Early-onset dementia | 65 at symptom onset | n/a | <45, 45–65 | 1, 2, 3, 4, 6, 7, 8, 29, 39, 57, 58a, 60, 73, 73c, 86, 134, 135 | n/a |
| Nordstrom et al. (2013) [ | Case-control study | 497844 | Hospital | Young-onset dementia, early-onset dementia | 65 | n/a | n/a | 1, 3, 4, 29, 73 Exclusion: 162, stroke, myocardinfarct | n/a Exclusion: Va |
| Phuapradit et al. (1978) [ | Comment | n/a | n/a | Presenile dementia | n/a | n/a | n/a | 1 | n/a |
| Rizzo et al. (1984) [ | Cross sectional study | 8 | Hospital | Presenile dementia | n/a | n/a | n/a | n/a | n/a |
| Rogers and Lippa (2012) [ | Review | n/a | n/a | Early-onset dementia | 65 | n/a | n/a | 1, 2, 2a, 2c-i, 2c-ii, 110, 112 | n/a |
| Ron et al. (1979) [ | Cross sectional study | 52 | Hospital | Presenile dementia | 65 at diagnosis | n/a | n/a | n/a Exclusion: 73, 77, 134, 147, space-occupying lesion, intracranial infection | n/a Exclusion: II, Vb, XI |
| Sansoni et al. (2016) [ | Review | n/a | n/a | Younger onset dementia, early onset dementia | 60, 65 at diagnosis | n/a | n/a | 1, 2, 3, 4, 8, 29, 57, 73, 161 | n/a |
| Smith et al. (1966) [ | Cross sectional study | 59 | Hospital | Presenile dementia | 65 at symptom onset | n/a | n/a | 1, 2, 29, 41, 58 | n/a |
| Spreadbury and Kipps (2019) [ | Review | n/a | n/a | Presenile dementia, young onset dementia, younger onset dementia | 65 | n/a | n/a | 1, 1a, 2, 2a, 2c, 2c-i, 2c-ii, 2c-iii, 3, 4, 6, 8, 29 | IVa |
| Torvik (1970) [ | Review | n/a | n/a | Presenile dementia | n/a | n/a | n/a | 1, 2, 29, 30, 32, 73, 58a | n/a |
| Vafeas et al. (2020) [ | Quasi-experimental study | n/a | n/a | Younger onset dementia | n/a | n/a | n/a | n/a | n/a |
| Vieira et al. (2013) [ | Review | n/a | n/a | Early-onset dementia, presenile dementia | 45, 60, 65 | 17 | <45, 45–65 | 1, 2, 2c-i, 2c-ii, 3, 4, 8, 29, 31, 57, 58a, 73, 134, 135, 161 | I |
| Wawrziczny et al. (2018) [ | Case-control study | 150 | Home and nursing home | Early-onset dementia | 65 at symptom onset | n/a | n/a | 1, 2, 3 | n/a |
| Withall (2013) [ | Editorial | n/a | n/a | Younger-onset dementia | 65 at symptom onset | 20 | 30–45, 45–65 | 1, 2, 3, 4, 8, 39, 57, 73, 134, 145, 161 | n/a |
| Woodburn and Johnstone (1999) [ | Cross sectional study | 126 | Home and nursing home | Early-onset dementia | n/a | n/a | n/a | 1, 31, 73 | n/a |
| Wright et al. (1984) [ | Experimental | 34 | Hospital | Presenile dementia | 70 at symptom onset | n/a | n/a | 1, 2, 8, 58a | n/a |
† See Table 4.